PANRETINAL PHOTOCOAGULATION PLUS INTRAVITREAL BEVACIZUMAB VERSUS PANRETINAL PHOTOCOAGULATION ALONE FOR PROLIFERATIVE DIABETIC RETINOPATHY

S  RIAZ; N AHMED; A KHAN; A JABRAN; I RAZA; T AFZAL

doi:10.54112/bcsrj.v2024i1.1313

Authors

S RIAZ Allama Iqbal Medical College Jinnah Hospital Lahore, Pakistan
N AHMED Department of Ophthalmology Nishtar Medical University Multan, Pakistan
A KHAN Department of Ophthalmology, Abbottabad International Medical Institute, Pakistan
A JABRAN Department of Ophthalmology LGH/PGMI, Lhr, Pakistan
I RAZA Department of Ophthalmology Govt. Shahbaz Sharif DHQ Hospital Multan, Pakistan
T AFZAL Department of VitreoRetina Al-Shifa Trust Eye Hopistal Rawalpindi, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2024i1.1313

Keywords:

Bevacizumab, Diabetic Retinopathy, Intravitreal Injections, Panretinal Photocoagulation, Proliferative Diabetic Retinopathy

Abstract

Proliferative diabetic retinopathy (PDR) is a severe and advanced stage of diabetic retinopathy, a major microvascular complication of diabetes mellitus. Objective: The basic aim of the study is to compare the panretinal photocoagulation plus intravitreal bevacizumab versus panretinal photocoagulation alone for proliferative diabetic retinopathy. Methodology: This randomized control trial was conducted at various tertiary care hospitals of Lahore and Rawalpindi from September 2023 to August 2024. Data include 40 patients, 80 eyes according to the study's criteria. Participants were randomly assigned into two equal groups using a computer-generated sequence. The first group, consisting of 20 patients, received PRP treatment alone and served as the control group. The second group, also consisting of 20 patients, received PRP combined with a single intravitreal injection of bevacizumab, forming the intervention group. Results: Both groups had a mean age of 54 ± 8 years and a male-to-female ratio of 3:2. Baseline best-corrected visual acuity (BCVA) was similar, with 0.4 ± 0.1 logMAR in the PRP group and 0.42 ± 0.1 logMAR in the combination group (p > 0.05). Central macular thickness (CMT) at baseline also showed no significant difference, with 310 ± 25 µm in the PRP group and 312 ± 27 µm in the combination group (p > 0.05), indicating well-matched groups for the study. Improvement in BCVA was significantly higher in the combination group (0.10 ± 0.03 logMAR) than in the PRP group (0.04 ± 0.02 logMAR, p = 0.02). Similarly, the reduction in central macular thickness (CMT) was more pronounced in the combination group (-22 ± 4 µm) compared to the PRP group (-5 ± 3 µm, p = 0.01). Conclusion: It is concluded that the combination of panretinal photocoagulation and intravitreal bevacizumab offers superior outcomes in managing proliferative diabetic retinopathy compared to PRP alone.

Downloads

Download data is not yet available.

References

Zhang W, Geng J, Sang A. Effectiveness of panretinal photocoagulation plus intravitreal anti-VEGF treatment against PRP alone for diabetic retinopathy: a systematic review with meta-analysis. Frontiers in Endocrinology. 2022;13:807687.

Yates WB, Mammo Z, Simunovic MP. Intravitreal anti-vascular endothelial growth factor versus panretinal LASER photocoagulation for proliferative diabetic retinopathy: a systematic review and meta-analysis. Canadian Journal of Ophthalmology. 2021;56(6):355-63.

Shaikh FF, Jatoi SM. Comparison of efficacy of combination therapy of an Intravitreal injection of bevacizumab and photocoagulation versus Pan Retinal Photocoagulation alone in High risk Proliferative Diabetic Retinopathy. Pakistan Journal of Medical Sciences. 2021;37(1):157.

Lang GE, Liakopoulos S, Vögeler J, Weiß C, Spital G, Gamulescu MA, et al. The RELATION study: efficacy and safety of ranibizumab combined with laser photocoagulation treatment versus laser monotherapy in NPDR and PDR patients with diabetic macular oedema. Acta ophthalmologica. 2018;96(3):e377-e85.

Preti RC, Mutti A, Ferraz DA, Zacharias LC, Nakashima Y, Takahashi WY, et al. The effect of laser pan-retinal photocoagulation with or without intravitreal bevacizumab injections on the OCT-measured macular choroidal thickness of eyes with proliferative diabetic retinopathy. Clinics. 2017;72(2):81-6.

Ali W, Abbasi KZ, Raza A. Panretinal photocoagulation plus Intravitreal Bevacizumab versus Panretinal photocoagulation alone for proliferative diabetic retinopathy. J Coll Physicians Surg Pak. 2018;28(12):923-7.

Figueira J, Fletcher E, Massin P, Silva R, Bandello F, Midena E, et al. Ranibizumab plus panretinal photocoagulation versus panretinal photocoagulation alone for high-risk proliferative diabetic retinopathy (PROTEUS study). Ophthalmology. 2018;125(5):691-700.

Wu L, Acón D, Wu A, Wu M. Vascular endothelial growth factor inhibition and proliferative diabetic retinopathy, a changing treatment paradigm? Taiwan journal of ophthalmology. 2019;9(4):216-23.

Choi W, Kang HG, Choi EY, Kim SS, Koh HJ, Kim M. Effect of intravitreal bevacizumab injection before panretinal photocoagulation on the prevention of macular edema aggravation in proliferative diabetic retinopathy. Journal of Clinical Medicine. 2020;9(11):3772.

Lopez-Lopez F, Gomez-Ulla F, Rodriguez-Cid M, Arias L. Triamcinolone and bevacizumab as adjunctive therapies to panretinal photocoagulation for proliferative diabetic retinopathy. International Scholarly Research Notices. 2012;2012(1):267643.

Wang X, Yao J, Li S, Zhang W, Wang L, Zhou A. Panretinal photocoagulation plus intravitreal conbercept for diabetic retinopathy in real world: a retrospective study. BMC ophthalmology. 2023;23(1):400.

Alsoudi AF, Wai KM, Koo E, Parikh R, Mruthyunjaya P, Rahimy E. Progression to Pars Plana Vitrectomy in Patients With Proliferative Diabetic Retinopathy. JAMA ophthalmology. 2024.

Arevalo JF, Beatson B. Pre-operative intravitreal bevacizumab for tractional retinal detachment secondary to proliferative diabetic retinopathy: the Alvaro Rodriguez lecture 2023. International Journal of Retina and Vitreous. 2023;9(1):29.

Ross EL, Hutton DW, Stein JD, Bressler NM, Jampol LM, Glassman AR, et al. Cost-effectiveness of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema treatment: analysis from the diabetic retinopathy clinical research network comparative effectiveness trial. JAMA ophthalmology. 2016;134(8):888-96.

Azad AD, Chen EM, Hinkle J, Rayess N, Wu D, Eliott D, et al. Anti–vascular endothelial growth factor and panretinal photocoagulation use after protocol S for proliferative diabetic retinopathy. Ophthalmology Retina. 2021;5(2):151-9.

Tao Y, Jiang P, Zhao Y, Song L, Ma Y, Li Y, et al. Retrospective study of aflibercept in combination therapy for high-risk proliferative diabetic retinopathy and diabetic maculopathy. International Ophthalmology. 2021;41:2157-65.

Chatziralli I, Dimitriou E, Theodossiadis G, Kazantzis D, Theodossiadis P. Intravitreal ranibizumab alone or in combination with panretinal photocoagulation for the treatment of proliferative diabetic retinopathy with coexistent macular edema: long-term outcomes of a prospective study. Acta Diabetologica. 2020;57:1219-25.